Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel
EHA Hybrid Congress 2023
Paolo Corradini, MD, of Italy’s Istituto Nazionale Dei Tumori, discusses findings from the CART-SIE Real Life Italian Study, which compared treatment outcomes for patients with relapsed or refractory primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL), all of whom received axicabtagene ciloleucel. The trial showed that those with PMBCL had superior survival outcomes than did those with DLBCL.
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase II study subgroup analysis that explored the question of whether ponatinib and blinatumomab, both active in Philadelphia chromosome–positive acute lymphoblastic leukemia, could offer an effective chemotherapy-free treatment for patients with newly diagnosed disease as well as reduce the need for allogeneic stem cell transplantation (Abstract S118).
The ASCO Post Staff
Nigel Russell, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, discusses the latest results from the AML19 trial, which showed the chemotherapy regimen FLAG-Ida (fludarabine, high-dose cytarabine, idarubicin, and granulocyte-colony stimulating factor), when combined with gemtuzumab ozogamicin, reduced levels of measurable residual disease and improved overall survival in patients with NPM1-mutated acute myeloid leukemia after induction therapy.
The ASCO Post Staff
Rami S. Komrokji, MD, of Moffitt Cancer Center, discusses an assessment of new classifications for myeloid neoplasms and the ongoing efforts to harmonize these classifications, so researchers can better understand risk, outcomes, and survival among patients with genetically distinct types of the disease.
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses new data on improved outcomes in patients with relapsed or refractory acute lymphoblastic leukemia who received the combination of mini-HCVD and reduced-dose inotuzumab and then blinatumomab in sequence. In mini-HCVD, cyclophosphamide and dexamethasone are administered with a 50% dose reduction, methotrexate with a 75% dose reduction, cytarabine with an 83% dose reduction, and anthracycline is omitted entirely. (Abstract S119)
The ASCO Post Staff
Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the final safety and efficacy results from the phase Ib/II CARTITUDE-1 trial of ciltacabtagene autoleucel. This CAR T-cell therapy targets B-cell maturation antigen in patients with relapsed or refractory multiple myeloma. Longer median progression-free survival was observed after a single infusion of this agent than any previously reported therapy in heavily pretreated patients (Abstract S202).
